Exane Derivatives’s Ero Copper ERO Stock Holding History

Exane Derivatives’s Portfolio ERO Stock Details ERO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,400	Closed	-$21.3K	–	1038
2021 Q4	$21.3K	Hold	1,400	–	–	0.01%	570
2021 Q3	$24.7K	Hold	1,400	–	–	0.01%	674
2021 Q2	$28.7K	Buy	+1,400	New	+$28.5K	0.01%	685

Other funds holding ERO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

IAM

Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Exane Derivatives's ERO Position: Q1 2022 in Review

Exane Derivatives sold out of Ero Copper (ERO) in Q1 2022, closing a stake of 1,400 shares — an estimated $21.3K sold.

Exane Derivatives first reported a position in ERO in Q2 2021 and held it in 3 quarters. The position peaked at $28.7K in Q2 2021. 78 funds tracked by Wall St. Rank hold ERO as of Q1 2022.

Exane Derivatives reported no remaining Ero Copper position as of Q1 2022 after selling out during the quarter.
Exane Derivatives sold 1,400 Ero Copper shares in Q1 2022, an estimated $21.3K.
Exane Derivatives first reported a position in Ero Copper in Q2 2021 and held it in 3 quarters.
Exane Derivatives's Ero Copper position peaked at $28.7K in Q2 2021.
78 funds tracked by Wall St. Rank held Ero Copper as of Q1 2022.

Based on Exane Derivatives's 13F filing for Q1 2022, filed 22 Apr 2022.